Pharma News

Adalimumab biosimilar by Biocon for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval

Adalimumab biosimilar is under clinical development by Biocon and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris).

Source link
#Adalimumab #biosimilar #Biocon #Plaque #Psoriasis #Psoriasis #Vulgaris #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *